in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
BMS Breaks Ground on Bio-Plant
1:23 PM MDT | August 9, 2007 | Chemical Week Editorial Staff
Bristol-Myers Squibb (BMS) says it has begun building a biologic drug manufacturing facility at Devens, MA. The facility is expected to cost about $750 million and is scheduled to start production in 2011, following regulatory approval in 2010. Final investment in the facility will total $1.1 billion, it says. The facility will feature six 20,000-liter cell culture reactor vessels and one purification line. It is being built primarily to manufacture BMS’s rheumatoid arthritis drug Orencia, which generated sales of $89 million in...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee